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Innovations in pneumonia diagnosis and treatment: a call to 
action on World Pneumonia Day, 2013 
In recognition of the 5th annual World Pneumonia 
Day on November 12, 2013, a call to action is being 
issued for innovations to defeat childhood pneumonia. 
Innovations to transform pneumonia diagnosis and 
treatment are urgently needed to tackle the leading 
cause of death in children younger than 5 years of 
age. Pneumonia causes more childhood deaths than 
do AIDS, malaria, and tuberculosis combined.1 Nearly 
all childhood pneumonia deaths are preventable 
through proper diagnosis and treatment. Yet less 
than a third of young children with symptoms of 
pneumonia receive treatment in low-resource settings,2 
where instruments to diagnose and treat pneumonia 
accurately are out of reach or unsuited to the needs 
of low-resource communities. The present rollout 
of Haemophilus inﬂ uenzae type b and Streptococcus 
pneumoniae conjugate vaccines shows promise to 
reduce childhood pneumonia mortality, while increased 
attention to maternal immunisation can potentially 
decrease neonatal mortality from inﬂ uenza, respiratory 
syncytial virus infection, group B streptococcal disease, 
and pertussis. Now is the time for a comprehensive 
approach to reduce pneumonia mortality that also 
includes promising diagnostic and treatment solutions. 
We should mobilise the resources, partnerships, and 
political will necessary to scale up existing instruments 
and accelerate the development of new innovations to 
revolutionise pneumonia diagnosis and treatment and 
save lives.
Pulse oximetry is the accepted standard for detection 
of hypoxaemia, an often fatal complication of 
pneumonia.3 Pulse oximetry is highly cost eﬀ ective 
and can accurately and reliably measure hypoxaemia, 
identifying 20–30% more cases than do clinical signs 
alone.4,5 Yet pulse oximetry is frequently unavailable 
in low-resource settings because of perceived cost, 
insuﬃ  cient supply, and absence of policies, guidelines, 
and training.6 Pulse oximetry could transform the 
diagnosis of hypoxaemia in low-resource settings, 
ensuring that oxygen is used eﬃ  ciently and rationally, 
easing timely referral decisions, reducing treatment 
failure rates, and decreasing health-care costs.7 Low-
cost pulse oximetry devices tailored for low-resource 
settings are in development, including mobile 
phone applications and alternatively-powered pulse 
oximeters.
Other diagnostic innovations in the pipeline include 
automated respiratory rate counters with a variety 
of technologies (accelerometers, small motion 
ampliﬁ cation programmes, and bioimpedance, 
among others), tracheal and chest auscultation with 
digital processing and analysis of respiratory sounds, 
and host response biomarkers such as inﬂ ammatory 
biomarkers (eg, C-reactive protein and procalcitonin), 
cardiovascular biomarkers (eg, arginine vasopressin 
and natriuretic peptides), and exhaled biomarkers 
(eg, volatile organic compounds). Combination of 
several diagnostic and prognostic innovations into an 
integrated instrument could improve identiﬁ cation of 
pneumonia and its severity. 
With training and appropriate support, community 
health workers can eﬀ ectively diagnose and treat 
childhood pneumonia in the community and increase 
access to high-quality care.8 Most pneumonia deaths 
are due to severe (chest indrawing) pneumonia,9 and 
in many low-resource settings, referral to facilities is 
diﬃ  cult and frequently does not occur.10,11 Therefore, 
case management of severe pneumonia at the 
community level is required. In two Pakistani studies, 
treatment failure rates were signiﬁ cantly reduced when 
community health workers treated severe pneumonia 
with oral amoxicillin for 5 days in the community 
compared with one dose of antibiotic and referral 
to the nearest health facility, the present standard 
of care.12,13
Ensuring that amoxicillin—WHO’s recommended ﬁ rst-
line treatment for childhood pneumonia—is available 
in child-friendly formulations is crucial to increasing 
its use.14 The availability of child-friendly 250 mg 
amoxicillin dispersible tablets should be improved to 
save lives, money, and health-care resources. Packaged 
in blister packs that are easy to dispense, manage, and 
withstand sunlight, heat, and rain, amoxicillin tablets 
quickly disperse in a small amount of clean water 
or breastmilk. Amoxicillin dispersible tablets have a 
longer shelf-life, do not need refrigeration, are more 
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cost eﬀ ective, and are easier to administer than other 
amoxicillin formulations. 
Other innovations in childhood pneumonia treatment 
are also in development, including a child-friendly 
product presentation of amoxicillin dispersible tablets 
to enable appropriate dispensing, administration, 
and adherence in the community. Discussion 
regarding the optimum duration of treatment with 
amoxicillin is under way, which could result in fewer 
days of treatment. Low-cost, electricity-free oxygen 
concentrators are also in development, as is oxygen-in-
a-box, which relies on chemical oxygen generation.
A comprehensive strategy to address childhood 
pneumonia should include the development and 
delivery of solutions designed for low-resource settings 
that are reliable, accurate, automatic, and appropriate 
for use in infants and young children. These innovations 
must be culturally acceptable, portable, resistant 
to water and dust, durable, and simple to use in the 
community. Through strategic partnerships, targeted 
investments, and our collective commitment, we 
can scale up existing instruments and prioritise the 
development of promising new innovations to protect 
the most vulnerable and save lives.
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